Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

Biotechnology • Healthcare • New York, NY, United States • TARA (NGM)

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

646 844 0337 345 Park Avenue South, New York, NY 10010, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Protara Therapeutics, Inc. (NASDAQ:TARA) is favoured by institutional owners who hold 74% of the company - Yahoo Finance
Yahoo Finance • Oct 28
Protara Therapeutics Raises $86.3 Million in Offering - TipRanks
TipRanks • Dec 15
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
GlobeNewswire • Nov 10
Protara Therapeutics stock falls despite positive lymphatic malformation trial data - Investing.com
Investing.com • Nov 19
Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Quiver Quantitative • Dec 4

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Protara Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Protara Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Protara Therapeutics, Inc. have?
Protara Therapeutics, Inc. has approximately 28 employees.
What industry is Protara Therapeutics, Inc. in?
Protara Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Protara Therapeutics, Inc. a publicly traded company?
Yes, Protara Therapeutics, Inc. is publicly traded under the ticker symbol TARA on the NGM. The company has a market capitalization of approximately $0.30 billion.
Where is Protara Therapeutics, Inc. headquartered?
Protara Therapeutics, Inc. is headquartered in New York, NY, United States at 345 Park Avenue South, New York, NY 10010, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.